Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.57 |
| ▸ | CPT1A | P50416 | 1/20 | 0.57 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60252 | 0.99 | CASP3 (0.67) | CASP3SENP7SENP6HSD11B1CPT1A | |
| SCHEMBL60197 | 0.97 | CASP3 (0.61) | CASP3SENP7SENP6HSD11B1CPT1A | |
| SCHEMBL60282 | 0.95 | CA12 (0.61) | CASP3SENP7SENP6HSD11B1CPT1A | |
| SCHEMBL23894371 | 0.87 | MEN1 (0.57) | CASP3SENP7SENP6HSD11B1CPT1A | |
| SCHEMBL60945 | 0.85 | MEN1 (0.55) | HSD11B1GRM5CA12CA1CA2 | |
| SCHEMBL20357464 | 0.82 | LMNA (0.55) | HSD11B1CPT1ACPT1BGRM5CYP2C9 | |
| SCHEMBL29176857 | 0.80 | CASP3 (0.56) | CASP3SENP7SENP6HSD11B1PPARA | |
| SCHEMBL30817748 | 0.80 | CASP3 (0.56) | CASP3SENP7SENP6HSD11B1PPARA | |
| SCHEMBL17014736 | 0.80 | CYP1A2 (0.74) | CASP3SENP7SENP6HSD11B1PPARA | |
| SCHEMBL16636594 | 0.80 | CASP3 (0.69) | CASP3SENP7SENP6PPARAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486982-B2 | 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| US-8227494-B2 | Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| JP-4851933-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1618098-A4 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT THERAPEUTICS INC (US) | 2008-07-16 | — | — | EP | claimed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | claimed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PCT THERAPEUTICS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | UPF1, RIOX2, RPL35A | CASP3 2242/4885SENP7 2825/4885SENP6 2801/4885 |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | CASP3 3421/4885SENP7 2853/4885SENP6 2894/4885 |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | UPF1, PABPC1, PABPC4 | CASP3 2918/4885SENP7 2646/4885SENP6 2247/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | CASP3 4452/4885SENP7 2618/4885SENP6 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.